Breast cancer management
Reading File
Finding Sources
Finding Sources
Searching PubMed
"breast cancer"[MeSH Terms] AND "management"[MeSH Terms]
Reading File
Reading File
Reading File
Reading File
Finding Sources
Finding Sources
Reading File
Reading File
I now have comprehensive content from multiple authoritative sources. Let me compile the full management overview.
Breast Cancer Management
1. Staging
Staging uses the AJCC 8th Edition TNM system, which now incorporates tumor size (T), lymph node status (N), metastasis (M), plus histologic grade, ER/PR/HER2 status, and genomic assays (e.g., Oncotype DX score).
| Stage | Tumor | Nodes | Metastasis | 10-yr Survival |
|---|---|---|---|---|
| 0 | DCIS | None | Absent | 97% |
| I | ≤2 cm invasive | None/micromet | Absent | 87% |
| II | >2 cm or >2–5 cm | 1–3 positive | Absent | 65% |
| III | >5 cm, or skin/chest wall, or inflammatory | ≥4 positive | Absent | 40% |
| IV | Any | Any | Present | 5% |
Source: Robbins, Cotran & Kumar Pathologic Basis of Disease
Prefixes/suffixes: y = post-neoadjuvant (ypTNM), r = recurrent (rTNM), m = multiple primaries.
2. In Situ Disease
Ductal Carcinoma In Situ (DCIS)
- Untreated DCIS → ~30% risk of subsequent invasive cancer in the same breast
- Management: Excision to negative margins ± ipsilateral breast radiotherapy ± endocrine therapy (if ER+) to reduce ipsilateral recurrence and contralateral primary risk
- Extensive DCIS → mastectomy; small burden → excision alone with mammographic surveillance
- Molecular assays can predict lack of benefit from radiotherapy after excision
Lobular Carcinoma In Situ (LCIS)
- Marker for increased risk (~25–30% develop invasive cancer in either breast)
- Management: Enhanced breast cancer screening + chemoprevention (tamoxifen or aromatase inhibitor)
- Bilateral prophylactic mastectomy reserved for those with additional high-risk features
3. Early-Stage Breast Cancer — Multidisciplinary Approach
Management is multidisciplinary, combining local therapy (surgery + radiation) and systemic therapy (to suppress micrometastatic disease and reduce distant recurrence/mortality).
Surgery
- Breast-conserving surgery (BCS/lumpectomy) + radiotherapy is equivalent in survival to modified radical mastectomy — established by 6 randomized trials
- Contraindications to BCS: patient preference, poor cosmesis, multifocal disease, prior chest radiation, ongoing pregnancy, extensive DCIS
- BRCA1/2 germline mutation → may drive decision for bilateral mastectomy due to high risk of subsequent cancer
- Mastectomy patients should be counseled on immediate or delayed reconstruction (autologous tissue or implants)
Axillary Management
- Clinically node-negative with small tumor → sentinel lymph node biopsy (SLNB) to guide staging and systemic therapy selection
- Axillary dissection (levels I–II) reserved for palpable nodes or substantial pathologic sentinel node involvement
- Recent trials support omitting SLNB in older women with small, biologically favorable ER+ tumors who will receive adjuvant endocrine therapy
- Omitting axillary dissection is supported for women with low sentinel node burden who will receive radiation
Radiation
- Whole-breast radiotherapy (WBR): standard 4–6 weeks; or hypofractionated schedules (5 days–3 weeks)
- Regional/axillary nodal extension of ports based on pathology and surgical approach
- Omission of RT may be safe in women >65 with low-risk ER+ tumors on endocrine therapy
- Post-mastectomy chest wall RT: for large tumors, ≥4 positive nodes; considered for 1–3 positive nodes or close margins
- Brachytherapy (direct application to tumor bed) is an option in selected cases
4. Systemic Therapy — Early Breast Cancer
Systemic therapy is given neoadjuvant (pre-op) or adjuvant (post-op).
Neoadjuvant vs. Adjuvant Selection
| Indication | Approach |
|---|---|
| HER2+ tumor ≥2 cm or node-positive | Neoadjuvant chemo + anti-HER2 agents |
| TNBC ≥2 cm or node-positive | Neoadjuvant chemo ± pembrolizumab (checkpoint inhibitor) |
| ER/PR+ postmenopausal (to reduce surgery extent) | Neoadjuvant endocrine therapy |
| Small tumors (any subtype) | Initial surgery → tailored adjuvant selection |
- Patients with TNBC who fail to achieve pCR after anthracycline + alkylator + taxane neoadjuvant regimen → benefit from subsequent capecitabine
- Achieving pathologic complete response (pCR) predicts better outcome
Endocrine Therapy (ER+/PR+)
- Tamoxifen / toremifene (SERMs): any menopausal status; block estrogen–ER interaction
- Aromatase inhibitors (anastrozole, letrozole, exemestane): postmenopausal women only as monotherapy
- Ovarian suppression (GnRH agonists: goserelin, leuprolide; or surgical oophorectomy): for premenopausal women, enabling use of aromatase inhibitors
- Duration: typically 5–10 years
- Adjuvant abemaciclib (CDK4/6 inhibitor): approved for high-risk HR+ early breast cancer (Ki-67 ≥20%), based on MonarchE trial
Anti-HER2 Therapy (HER2+)
- Trastuzumab: the backbone; combined with chemotherapy (e.g., paclitaxel); ~30% response as monotherapy in metastatic disease
- Pertuzumab: added to trastuzumab + taxane in neoadjuvant/adjuvant setting for node-positive or locally advanced disease
- T-DM1 (ado-trastuzumab emtansine): for residual HER2+ disease after neoadjuvant therapy (established by KATHERINE trial)
Chemotherapy Regimens (Early-Stage)
- Multiagent regimens standard in early breast cancer
- Typically include anthracycline (doxorubicin/epirubicin) + taxane (paclitaxel/docetaxel) ± alkylating agents (cyclophosphamide)
- In TNBC: pembrolizumab (PD-1 inhibitor) added to neoadjuvant chemo and continued as adjuvant for high-risk disease
PARP Inhibitors
- Olaparib / talazoparib: for patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer after adjuvant chemotherapy
5. Metastatic Breast Cancer
Management is driven by molecular subtype and prior therapy. Goals shift from curative to disease control, palliation, and quality of life.
HR+/HER2− Metastatic Disease
First-line (treatment-naive metastatic disease):
- Postmenopausal: Aromatase inhibitor + CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib)
- Premenopausal: LHRH agonist + aromatase inhibitor + CDK4/6 inhibitor
- Median PFS ~2 years; median OS >3 years with these regimens
Recurrent/refractory disease:
| Situation | Option |
|---|---|
| ESR1 mutation + prior CDK4/6i + prior AI | Elacestrant (oral SERD) |
| No ESR1 mutation | Fulvestrant ± CDK4/6 inhibitor (if CDK4/6i-naive) |
| PIK3CA mutation | Alpelisib + fulvestrant |
| PIK3CA/AKT1/PTEN alteration (1 prior ET) | Capivasertib + fulvestrant |
| No targetable mutations | Everolimus (mTOR inhibitor) + aromatase inhibitor |
CDK4/6 inhibitors compared:
| Agent | Key Toxicity |
|---|---|
| Palbociclib | Neutropenia (higher) |
| Ribociclib | Neutropenia, QTc prolongation |
| Abemaciclib | Diarrhea, fatigue (less myelosuppression) |
HER2+ Metastatic Disease
- First-line: Taxane + pertuzumab + trastuzumab (dual HER2 blockade)
- After progression: T-DXd (trastuzumab deruxtecan) — highly effective antibody-drug conjugate
- Margetuximab (Fc-optimized anti-HER2): for trastuzumab-refractory patients (SOPHIA trial)
- Lapatinib (TKI): option in later lines; combination with capecitabine or trastuzumab
- Tucatinib + trastuzumab + capecitabine: active in CNS metastases (HER2CLIMB trial)
Triple-Negative Metastatic Breast Cancer (TNBC)
- Chemotherapy backbone: sequential single-agent preferred over combination (except visceral crisis)
- Capecitabine (oral; check DPYD mutation status before starting)
- Taxanes, anthracyclines (if not previously used), vinorelbine, gemcitabine, eribulin
- Pembrolizumab + chemotherapy: for PD-L1 CPS ≥10 (KEYNOTE-522/355)
- Sacituzumab govitecan (TROP-2 ADC): for 2+ prior therapies
- Olaparib / talazoparib: for germline BRCA1/2-mutated TNBC
- Combination chemotherapy over sequential monotherapy does not improve OS in metastatic TNBC; reserve for visceral crisis only
Bone Metastases
- Bisphosphonates (zoledronic acid) or denosumab: reduce skeletal-related events in bone-metastatic disease
- Radiation and orthopedic stabilization as needed
6. Special Situations
| Situation | Key Consideration |
|---|---|
| Inflammatory breast cancer | Always stage III+; requires neoadjuvant chemo → surgery → radiation |
| DCIS extensive | Mastectomy required |
| BRCA1/2 carriers | Consider bilateral mastectomy; PARP inhibitors if high-risk |
| Pregnancy | Systemic therapy generally avoided in 1st trimester; surgery and some chemo possible in 2nd/3rd trimester |
| Male breast cancer | 1% of all breast cancers; BRCA2 most important genetic risk; tamoxifen backbone of endocrine therapy |
| Elderly / comorbid | May omit SLNB, RT, or intensive chemo with tailored decision-making |
7. Molecular Subtypes & Treatment Summary
| Subtype | Markers | Key Systemic Therapy |
|---|---|---|
| Luminal A | ER+/PR+, HER2−, low grade, low Ki-67 | Endocrine therapy ± CDK4/6i; minimal chemo benefit |
| Luminal B | ER+, HER2−, high Ki-67 or HER2+ | Endocrine + chemo; anti-HER2 if HER2+ |
| HER2-enriched | ER−/PR−, HER2+ | Chemo + dual anti-HER2 (pertuzumab + trastuzumab) |
| TNBC | ER−/PR−, HER2− | Chemo ± immunotherapy ± PARP inhibitors (BRCA) |
8. Genomic Tools for Decision-Making
- Oncotype DX (Recurrence Score): most validated in ER+/HER2− early breast cancer; scores <26 indicate endocrine therapy alone is sufficient (TAILORx/RxPONDER trials)
- MammaPrint, Prosigna, EndoPredict: alternative genomic assays for similar clinical decisions
- ESR1 mutation testing (liquid or tissue biopsy): guides use of elacestrant in metastatic setting
- PIK3CA/AKT/PTEN mutation testing: guides use of alpelisib/capivasertib
Sources: Harrison's Principles of Internal Medicine 22E (2025), Robbins & Cotran Pathologic Basis of Disease, Sabiston Textbook of Surgery, Current Surgical Therapy 14e, Goldman-Cecil Medicine
This is a shared conversation. Sign in to Orris to start your own chat.